5 Papers That Show Where AI Research Is Heading Right Now
This compilation synthesizes five papers and YC conversations pointing to the near‑term research directions reshaping AI: scaling foundation models for proteins, AlphaZero‑style self‑play for language models, streaming RAG for real‑time voice agents, formal verification tooling, and agentic programming workflows. These are directional signals for investors sizing exposure to AI‑driven biology and developer tooling—valuable for strategic positioning but not immediate, dateable catalysts.
Linked assets
Two public tickers are relevant as optionality plays on AI‑first biology and computational discovery: RXRX (preclinical therapeutics pipeline including REC‑7735 and REC‑102) and SDGR (a company split between Software and Drug Discovery). Both could benefit if protein foundation models and related biology modeling approaches gain traction, but timelines are likely multi‑year and outcomes uncertain.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
Direct narrative linkage to AI-first biology; high optionality, high volatility, long feedback loops.
The company operates in two segments, Software and Drug Discovery.
Computational discovery platform exposure; benefits if protein/biology modeling attention expands.
Source proof
Source proof: Strong source proof | 6 extracted claims | 2 directional assets | 1 supporting author | headline-like title review
Sources include a YC Paper Club recap and multiple YC interviews/podcasts that discuss emerging AI research themes. The central evidence is thematic: research directions, product/workflow experiments, and strategic commentary from founders—not specific, near‑term commercial milestones or public‑company disclosures.
Content is a YC Startup School talk about building durable startups in the AI era. The actionable market-relevant bits are mostly high-level: (1) intelligence/AI inference is getting much cheaper, (2) moats shift away from “model choice” toward distribution, product loops, data/workflows, and founder execution, and (3) US export restrictions on frontier AI matter. No explicit company mentions or investable calls, so tickers are inferred by theme (AI compute stack, hyperscalers, and export-control-exposed semis).
Talk-level, largely qualitative discussion about AI startups vs Big Tech, with mentions of LLM limits, “world models,” robotics, and continued need for large-scale GPU compute. Actionability is low because there are no concrete catalysts, numbers, or near-term company-specific claims; the most tradable takeaway is a continued AI compute/infra demand narrative (GPU/accelerators, foundry, advanced packaging).
YC talk argues “Physical AI” (AI applied to the physical economy via multimodal sensing/robotics/automation) is the next platform shift; content is conceptual with limited concrete catalysts, but maps to tradable beneficiaries in GPUs/edge compute, industrial automation, and sensor/vision stacks.
Interview-style content about Opencode (open-source Claude Code alternative) claiming rapid adoption (13M MAUs, 20x growth) and heavy token usage, framed around (1) open-source models becoming “good enough,” (2) enterprise adoption of coding agents, (3) model-choice flexibility and token economics, and (4) platform risk illustrated by Anthropic allegedly attempting to block Opencode, which backfired via attention/distribution.
Interview-style content about Photoroom (private) describing how Y Combinator increased founders’ ambition and execution mindset; little concrete product/financial data and no public-company catalysts. Limited direct trading actionability beyond a broad “AI image editing / creator tools / e-commerce enablement” narrative.
YC Startup School talk with Dust co-founder argues no single AI lab will dominate; model-agnostic application/platform layer may be a moat. Notes funding being absorbed by frontier labs, raises small by design, and highlights margin compression at the token/model level, making unit economics challenging for AI apps that resell model tokens.
YC Startup School talk: Supabase grew rapidly by offering an open-source, Postgres-based alternative to Firebase/RDS with very fast time-to-value; claims a $500M round and $10B valuation; positions “open source wins the LLM/agent era” and suggests AI agents are becoming core users. Supabase is private, but narrative has read-through to public cloud, database, and devtool vendors.
Podcast-style discussion with PostHog CEO James Hawkins on startup strategy (ambition as GTM, product expansion, founder mindset) and some broad AI/dev tooling themes (LLMs, “recursive AI loop,” intent data, AI-assisted pull requests). No concrete company-specific news, financials, or tradable catalysts.
Supporting authors
Summaries are drawn from a single author’s compilation of YC content and related talks. The material emphasizes research direction and founder perspectives rather than granular market metrics.
Unlock full thesis monitoring
Treat protein foundation models and AI‑first biology as longer‑duration, optionality investments. If you want to increase conviction, monitor: (1) demonstrable performance gains in protein modeling benchmarks, (2) partnerships or licensing between model groups and drug developers, and (3) early translational milestones (validated leads, INDs).